Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drug

Zentralblatt fur Neurochirurgie

Volumn 71, Issue 3, 2010, Pages 139-142

  Kast, R E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

auranofin; cathepsin B; extracellular matrix; glioblastoma; urokinase

Indexed keywords

AURANOFIN; CATHEPSIN B; PLASMINOGEN ACTIVATOR; PYRIDOXINE; THIOREDOXIN REDUCTASE; UROKINASE;

BLOOD BRAIN BARRIER; CANCER INVASION; GLIOBLASTOMA; HUMAN; NONHUMAN; OVERALL SURVIVAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; AURANOFIN; BRAIN NEOPLASMS; CATHEPSIN B; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; VITAMIN B 6;

EID: 77956025867     PISSN: 00444251     EISSN: 14389746     Source Type: Journal    
DOI: 10.1055/s-0029-1242756     Document Type: Review

References (41)

1. Lefranc F, Sadeghi N, Camby I, etal. Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther 2006 6 5 719-732
2. Hayashi Y, Edwards NA, Proescholdt MA, etal. Regulation and function of aquaporin-1 in glioma cells. Neoplasia 2007 9 777-787
3. Strojnik T, Kavalar R, Trinkaus M, etal. Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect Prev 2005 29 448-455
4. Wang M, Tang J, Liu S, etal. Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol 2005 71 3-7
5. Gondi CS, Lakka SS, Yanamandra N, etal. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 2004 64 4069-4077
6. Mai J, Sameni M, Mikkelsen T, etal. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem 2002 383 1407-1413
7. Strojnik T, Zajc I, Bervar A, etal. Cathepsin B and its inhibitor stefin A in brain tumors. Pflugers Arch 2000 439 3 Suppl R122-R123
8. Strojnik T, Kos J, Zidanik B, etal. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 1999 5 559-567
9. Mikkelsen T, Yan PS, Ho KL, etal. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J Neurosurg 1995 83 285-290
10. Colin C, Voutsinos-Porche B, Nanni I, etal. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 2009 Sept 23 [Epub ahead of print] PubMed PMID: 19774387
11. Rempel SA, Rosenblum ML, Mikkelsen T, etal. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 1994 54 6027-6031
12. Yamamoto M, Ueno Y, Hayashi S, etal. The role of proteolysis in tumor invasiveness in glioblastoma and metastatic brain tumors. Anticancer Res 2002 22 4265-4268
13. Levicar N, Nuttall RK, Lah TT. Proteases in brain tumour progression. Acta Neurochir (Wien) 2003 145 825-838
14. Lakka SS, Gondi CS, Yanamandra N, etal. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004 23 4681-4689
15. Yanamandra N, Gumidyala KV, Waldron KG, etal. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 2004 23 2224-2230
16. Konduri SD, Yanamandra N, Siddique K, etal. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2002 21 8705-8712
17. Mohanam S, Jasti SL, Kondraganti SR, etal. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2001 20 3665-3673
18. Werle B, Ebert W, Klein W, etal. Cathepsin B in tumors, normal tissue and isolated cells from the human lung. Anticancer Res 1994 14 1169-1176
19. Iwatsuki K, Kumara E, Yoshimine T, etal. Elastase expression by infiltrating neutrophils in gliomas. Neurol Res 2000 22 5 465-468
20. Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol 1997 36 560-572
21. Gunatilleke SS, de Oliveira CA, McCammon JA, etal. Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study. J Biol Inorg Chem 2008 13 555-561
22. Gunatilleke SS, Barrios AM. Tuning the Au(I)-mediated inhibition of cathepsin B through ligand substitutions. J Inorg Biochem 2008 102 555-563
23. Cox AG, Brown KK, Arner ES, etal. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 2008 76 1097-1109
24. Talbot S, Nelson R, Self WT. Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia. Br J Pharmacol 2008 154 940-948
25. Becker K, Gromer S, Schirmer RH, etal. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 2000 267 6118-6125
26. Marzano C, Gandin V, Folda A, etal. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 2007 42 872-881
27. Tiekink ER. Anti-cancer potential of gold complexes. Inflammopharmacology 2008 16 138-142
28. Inubushi T, Okada M, Matsui A, etal. Effect of dietary vitamin B6 contents on antibody production. Biofactors 2000 11 93-96
29. Katunuma N, Matsui A, Endo K, etal. Inhibition of intracellular cathepsin activities and suppression of immune responses mediated by helper T lymphocyte type-2 by peroral or intraperitoneal administration of vitamin B. Biochem Biophys Res Commun 2000 272 151-155
30. Katunuma N, Matsunaga Y, Matsui A, etal. Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption. Adv Enzyme Regul 1998 38 235-251
31. Snodgrass SR. Vitamin neurotoxicity. Mol Neurobiol 1992 6 41-73
32. Guo M, Mathieu PA, Linebaugh B, etal. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-beta. A process initiated by the exocytosis of cathepsin B. J Biol Chem 2002 277 14829-14837
33. Kobayashi H, Moniwa N, Sugimura M, etal. Effects of membrane-associated cathepsin B on the activation of receptor-bound pro-urokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1993 1178 55-62
34. Salajegheh M, Rudnicki A, Smith TW. Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. Appl Immunohistochem Mol Morphol 2005 13 184-189
35. Zhao Y, Lyons CE Jr, Xiao A, etal. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochem Biophys Res Commun 2008 369 1215-1220
36. Gole B, Durán Alonso MB, Dolenc V, etal. Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol Oncol Res 2009 May 13 [Epub ahead of print] PMID: 19434518
37. Kast RE. Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question. Clin Transl Oncol 2009 11 7 408-410
38. Kast RE, Belda-Iniesta C. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: An hypothesis. Curr Stem Cell Res Ther 2009 Dec 1 [Epub ahead of print] PubMed PMID: 19500061
39. Kast RE, Altschuler EL. Current drugs available now for interleukin-6 suppression as treatment adjunct in glioblastoma: anakinra, aprepitant, mirtazapine and olanzapine. Int J Cancer Res 2006 2 303-314
40. Kuhn SA, Mueller U, Hanisch UK, etal. Glioblastoma cells express functional cell membrane receptors activated by daily used medical drugs. J Cancer Res Clin Oncol 2009 Jun 19 PubMed PMID: 19543745
41. Carapancea M, Alexandru O, Fetea AS, etal. Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol 2009 92 2 137-147